ACHE and metabolic syndrome: Centrally acting cholinergic drugs such as the acetylcholinesterase (AChE) inhibitor galantamine alleviate inflammation in preclinical settings of endotoxemia, inflammatory bowel disease, lupus, metabolic syndrome and other disorders (Pavlov et al., 2009; Ji et al., 2014; Pavlov and Tracey, 2015; Pham et al., 2018; Lehner et al., 2019; Metz and Pavlov, 2020).